Bridge Biotherapeutics has entered an exclusive in-licensing agreement with Shaperon to develop BBT-209, an investigational therapy for idiopathic pulmonary fibrosis (IPF). “We hope that BBT-209 will become a breakthrough therapy for patients with IPF, who are currently lacking treatment options,” Seung-Yong Seong, MD, PhD and Myung-Sea Lee, MD,…
The European Commission is expected to propose a new governing framework for health data next month, called the European Health Data Space (EHDS), with the aim of connecting national health systems to facilitate secure and efficient transfer of data across systems in different European nations. The move is expected to…
The National Organization for Rare Disorders (NORD) has updated its State Report Card to make it more digitally friendly and added telehealth to its categories of rare disease policy issues in a nod to its increased use during the ongoing COVID-19 pandemic. NORD’s report card project began seven…
Oral therapies that kill aging cells were found to boost the levels of alpha-Klotho, a protective protein that declines with age and safeguards animals against age-related diseases — including idiopathic pulmonary fibrosis (IPF) — in a study involving older mice. So-called senolytic therapies are designed to kill aging senescent…
Using nanoparticles to deliver an anti-scarring RNA molecule to pro-scarring lung macrophages — a type of immune cell — prevented and reduced lung tissue fibrosis in a mouse model of pulmonary fibrosis (PF), a study shows. To specifically target pro-fibrotic macrophages, researchers at University of Illinois College of Medicine (UICM)…
Abnormally high levels of the signaling molecule interleukin 19 (IL-19) were detected in lung tissues from both mice and humans with idiopathic pulmonary fibrosis (IPF) in a recent study. These findings indicate that IL-19 promotes IPF progression by activating the transforming growth factor-beta pathway, a key mediator of tissue…
Angion Biomedica plans to ask the U.S. Food and Drug Administration (FDA) for permission to start testing its experimental therapy ANG-3070 in people with idiopathic pulmonary fibrosis (IPF), the company announced. ANG-3070 is an oral medication designed to block the activity of multiple protein receptors that contribute to…
Ube Industries and HiLung are teaming up to advance HL001, an experimental therapy to prevent disease progression in idiopathic pulmonary fibrosis (IPF). The companies, both based in Japan, anticipate launching clinical studies of HL001 in people by March 2024. “This most recent agreement solidifies the collaboration between Ube Industries…
Healthcare providers involved in diagnosing and treating rare diseases believe that increased physician education and collaboration with specialized facilities will have the greatest positive impact on treating these conditions over the next five years, according to results from a 2021 survey. Definitive Healthcare, a healthcare commercial intelligence company, conducted…
An extract of the plant Lemna minor L., also called duckweed, suppresses the signs and symptoms of idiopathic pulmonary fibrosis (IPF) in disease-induced mice, a study suggests. More research to evaluate dosing and oral availability is recommended, study authors noted. “Pulmonary Protein Oxidation and Oxidative Stress…
Get regular updates to your inbox.
